Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM21menos65 phase III trial in transplant-eligible newly diagnosed multiple myeloma
2021-004130-11Phase 3Active
- Sponsor
- PETHEMA
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab, iberdomide, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by PETHEMA. Primary endpoint: MRD negativity after 18 cycles plus ASCT. Started May 2022; status: active.
02
Drugs
isatuximabiberdomidelenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-004130-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004130-11.